메뉴 건너뛰기




Volumn 11, Issue 4, 2011, Pages 383-393

Cost-effectiveness of sunitinib in metastatic renal cell carcinoma

Author keywords

computer simulation; cost effectiveness; kidney cancer; QALY; RCC; sunitinib

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; INTERLEUKIN 2; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

EID: 80051736592     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.11.33     Document Type: Article
Times cited : (11)

References (55)
  • 2
    • 42649145828 scopus 로고    scopus 로고
    • Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review
    • Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat. Rev. 34, 193-205 (2008).
    • (2008) Cancer Treat. Rev. , vol.34 , pp. 193-205
    • Gupta, K.1    Miller, J.D.2    Li, J.Z.3    Russell, M.W.4    Charbonneau, C.5
  • 8
    • 68949145218 scopus 로고    scopus 로고
    • Overall survival and updated results for sunitinib versus interferon a in first-line treatment of patients with metastatic renal cell carcinoma
    • Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib versus interferon a in first-line treatment of patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 3584-3590 (2009).
    • (2009) J. Clin. Oncol. , vol.27 , pp. 3584-3590
    • Motzer, R.J.1    Hutson, T.E.2    Tomczak, P.3
  • 9
    • 77949429364 scopus 로고    scopus 로고
    • Sunitinib for the management of advanced renal cell carcinoma
    • Escudier B. Sunitinib for the management of advanced renal cell carcinoma. Expert Rev. Anticancer Ther. 10(3), 305-317 (2010).
    • (2010) Expert Rev. Anticancer Ther , vol.10 , Issue.3 , pp. 305-317
    • Escudier, B.1
  • 10
    • 66549108544 scopus 로고    scopus 로고
    • Renal cell carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up
    • Escudier B, Kataja V. Renal cell carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 20 (Suppl. 4), iv81-iv82 (2009).
    • (2009) Ann. Oncol. , vol.20 , Issue.SUPPL. 4
    • Escudier, B.1    Kataja, V.2
  • 11
    • 48649107474 scopus 로고    scopus 로고
    • Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomized, placebo controlled Phase III trial
    • Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo controlled Phase III trial. Lancet 372, 449-456 (2008).
    • (2008) Lancet , vol.372 , pp. 449-456
    • Motzer, R.J.1    Escudier, B.2    Oudard, S.3
  • 12
    • 77951582589 scopus 로고    scopus 로고
    • Sunitinib, sorafenib, temsirolimus or bevacizumab in the treatment of metastatic renal cell carcinoma: A review of health economic evaluations
    • Norum J, Nieder C, Kondo M. Sunitinib, sorafenib, temsirolimus or bevacizumab in the treatment of metastatic renal cell carcinoma: a review of health economic evaluations. J. Chemother. 22(2), 75-82 (2010).
    • (2010) J. Chemother , vol.22 , Issue.2 , pp. 75-82
    • Norum, J.1    Nieder, C.2    Kondo, M.3
  • 13
    • 84857104145 scopus 로고    scopus 로고
    • Economic evaluation of sunitinib vs. interferon-A (IFN-a) in first-line metastatic renal cell carcinoma (mRCC
    • Négrier S, Remák E, Brown Rl, Kim ST, Charbonneau C, Motzer RJ. Economic evaluation of sunitinib vs. interferon-a (IFN-a) in first-line metastatic renal cell carcinoma (mRCC). Eur. J. Cancer 5(Suppl. 4), 303 (2007).
    • (2007) Eur. J. Cancer , vol.5 , Issue.SUPPL. 4 , pp. 303
    • Négrier, S.1    Remák, E.2    Rl, B.3    Kim, S.T.4    Charbonneau, C.5    Motzer, R.J.6
  • 14
    • 75349102521 scopus 로고    scopus 로고
    • Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: A systematic review and economic evaluation
    • Thompson Coon J, Hoyle M, Green C et al. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. Health Technol. Assess. 14 (2), 1-184 (2010).
    • (2010) Health Technol. Assess. , vol.14 , Issue.2 , pp. 1-184
    • Thompson Coon, J.1    Hoyle, M.2    Green, C.3
  • 15
    • 0031886073 scopus 로고    scopus 로고
    • An introduction to Markov modelling for economic evaluation
    • DOI 10.2165/00019053-199813040-00003
    • Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 13(4), 397-409 (1998). (Pubitemid 28140699)
    • (1998) PharmacoEconomics , vol.13 , Issue.4 , pp. 397-409
    • Briggs, A.1    Sculpher, M.2
  • 16
    • 80051733969 scopus 로고    scopus 로고
    • Sorafenib and sunitinib in metastatic renal cell carcinoma: Cost-effectiveness analysis in reimbursement proceedings vs. data from clinical practice
    • Prague, Czech Republic, 6-9 November
    • Ondrackova B, Demlova R. Sorafenib and sunitinib in metastatic renal cell carcinoma: cost-effectiveness analysis in reimbursement proceedings vs. data from clinical practice. Presented at : ISPOR 13th Annual European Congress. Prague, Czech Republic, 6-9 November 2010.
    • (2010) ISPOR 13th Annual European Congress
    • Ondrackova, B.1    Demlova, R.2
  • 17
    • 50549086998 scopus 로고    scopus 로고
    • Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma
    • Remák E, Charbonneau C, Négrier S, Kim ST, Motzer RJ. Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma. J. Clin. Oncol. 26(24), 3995-4000 (2008).
    • (2008) J. Clin. Oncol , vol.26 , Issue.24 , pp. 3995-4000
    • Remák, E.1    Charbonneau, C.2    Négrier, S.3    Kim, S.T.4    Motzer, R.J.5
  • 18
    • 77956373891 scopus 로고    scopus 로고
    • How do cost-effectiveness analyses inform reimbursement decisions for oncology medicines in Canada? the example of sunitinib for first-line treatment of metastatic renal cell carcinoma
    • Chabot I, Rocchi A. How do cost-effectiveness analyses inform reimbursement decisions for oncology medicines in Canada? The example of sunitinib for first-line treatment of metastatic renal cell carcinoma. Value Health 13(6), 837-845 (2010).
    • (2010) Value Health , vol.13 , Issue.6 , pp. 837-845
    • Chabot, I.1    Rocchi, A.2
  • 19
    • 80051746090 scopus 로고    scopus 로고
    • Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma
    • DOI: 10. 1111/j. 1464-410X.2010 (Epub ahead of print)
    • Benedict A, Figlin RA, Sandström P et al. Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma. BJU Int. DOI: 10. 1111/j. 1464-410X. 2010. 09957 (2011) (Epub ahead of print).
    • (2011) BJU Int. , pp. 09957
    • Benedict, A.F.1
  • 20
    • 84857101219 scopus 로고    scopus 로고
    • Sunitinib vs. interferon-A (IFN-a) in first-line metastatic renal cell carcinoma (mRCC): An economic evaluation
    • Remák E, Brown R, Négrier S, Motzer RJ, Kim ST, Charbonneau C. Sunitinib vs. interferon-a (IFN-a) in first-line metastatic renal cell carcinoma (mRCC): An economic evaluation. Value Health 10(6), A327-A328 (2007).
    • (2007) Value Health , vol.10 , Issue.6
    • Remák, E.1    Brown, R.2    Négrier, S.3    Motzer, R.J.4    Kim, S.T.5    Charbonneau, C.6
  • 21
    • 44349126126 scopus 로고    scopus 로고
    • Economic evaluations of sunitinib versus interferon-A (IFN-α) in first-line metastatic renal cell carcinoma (mRCC
    • (Abstract 6607
    • Remαk E, Mullins CD, Akobundu E, Charbonneau C, Woodruff K. Economic evaluations of sunitinib versus interferon-a (IFN-α) in first-line metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 25(Suppl. 18S) (2007) (Abstract 6607).
    • (2007) J. Clin. Oncol , vol.25 , Issue.SUPPL. 18
    • Remák, E.1    Mullins, C.D.2    Akobundu, E.3    Charbonneau, C.4    Woodruff, K.5
  • 22
    • 80051774942 scopus 로고    scopus 로고
    • Economic implications of the first line treatment of advanced renal cell carcinoma in Thailand: A cost-effectiveness analysis
    • Phuket, Thailand, 5-7 September
    • Topibulpong N, Tanasanvimon S, Parinyanitikul N, Vinayanuwattikun C, Sriuranpong V. economic implications of the first line treatment of advanced renal cell carcinoma in Thailand: a cost-effectiveness analysis. Presentedt at: ISPOR 4th Asia-Pacific Conference. Phuket, Thailand, 5-7 September 2010.
    • (2010) ISPOR 4th Asia-Pacific Conference
    • Topibulpong, N.1    Tanasanvimon, S.2    Parinyanitikul, N.3    Vinayanuwattikun, C.4    Sriuranpong, V.5
  • 23
    • 84857107569 scopus 로고    scopus 로고
    • Economic evaluation of sunitinib versus other new targeted therapies as first-line treatment of metastatic renal cell carcinoma (mRCC) in the United States
    • Abstract 17556
    • Benedict A, Figlin RA, Charbonneau C, Kreif N, Hariharan S, Négrier S. Economic evaluation of sunitinib versus other new targeted therapies as first-line treatment of metastatic renal cell carcinoma (mRCC) in the United States. J. Clin. Oncol. 27 (2009) (Abstract 17556).
    • (2009) J. Clin. Oncol. , vol.27
    • Benedict, A.1    Figlin, R.A.2    Charbonneau, C.3    Kreif, N.4    Hariharan, S.5    Négrier, S.6
  • 24
    • 84857102175 scopus 로고    scopus 로고
    • Cost effectiveness analysis of sunitinib, bevacizumab plus interferon-A and temsirolimus as first-line therapy of metastatic renal cell carcinoma in Sweden
    • Remák E, Vioix H, Sandin R, Harmenberg U, Ullen A, Sandstom P. Cost effectiveness analysis of sunitinib, bevacizumab plus interferon-a and temsirolimus as first-line therapy of metastatic renal cell carcinoma in Sweden. Value Health 12(7), A270 (2009).
    • (2009) Value Health , vol.12 , Issue.7
    • Remák, E.1    Vioix, H.2    Sandin, R.3    Harmenberg, U.4    Ullen, A.5    Sandstom, P.6
  • 25
    • 80051720645 scopus 로고    scopus 로고
    • Cost-effectiveness analysis of temsirolimus vs. sunitinib malate in poor prognosis metastatic renal cell carcinoma (mRCC) in Portugal
    • Silverio NM, Yang S, Alemao E. Cost-effectiveness analysis of temsirolimus vs. sunitinib malate in poor prognosis metastatic renal cell carcinoma (mRCC) in Portugal. Value Health 12(7), A271 (2009).
    • (2009) Value Health , vol.12 , Issue.7
    • Silverio, N.M.1    Yang, S.2    Alemao, E.3
  • 26
    • 77954522229 scopus 로고    scopus 로고
    • Cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: Perspective of the Spanish National Health System
    • Paz-Ares L, del Muro JG, Grande E, Díaz S. Cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish National Health System. J. Clin. Pharm. Ther. 35(4), 429-438 (2010).
    • (2010) J. Clin. Pharm. Ther , vol.35 , Issue.4 , pp. 429-438
    • Paz-Ares, L.1    Del Muro, J.G.2    Grande, E.3    Díaz, S.4
  • 27
    • 41549092232 scopus 로고    scopus 로고
    • Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland
    • DOI 10.1016/j.clinthera.2008.02.013, PII S0149291808000969
    • Purmonen T, Martikainen JA, Soini EJ, Kataja V, Vuorinen RL, Kellokumpu- Lehtinen PL. Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland. Clin. Ther. 30(2), 382-392 (2008). (Pubitemid 351474383)
    • (2008) Clinical Therapeutics , vol.30 , Issue.2 , pp. 382-392
    • Purmonen, T.1    Martikainen, J.A.2    Soini, E.J.O.3    Kataja, V.4    Vuorinen, R.-L.5    Kellokumpu-Lehtinen, P.-L.6
  • 29
    • 77954471321 scopus 로고    scopus 로고
    • Sunitinib malate provides additional survival and value for money as a second line treatment for metastatic renal cell carcinoma (mRCC) - An economic evaluation using Bayesian approach
    • Purmonen T, Martikainen JA, Soini EJ, Kataja V, Kellokumpu-Lehtinen PL. Sunitinib malate provides additional survival and value for money as a second line treatment for metastatic renal cell carcinoma (mRCC) - an economic evaluation using Bayesian approach. Value Health 10(6), A337 (2007).
    • (2007) Value Health , vol.10 , Issue.6
    • Purmonen, T.1    Martikainen, J.A.2    Soini, E.J.3    Kataja, V.4    Kellokumpu-Lehtinen, P.L.5
  • 30
    • 77954473386 scopus 로고    scopus 로고
    • Cost-effectiveness of sunitinib as second line treatment in patients with metastatic renal cancer in Belgium
    • van Nooten F, Dewilde S, Van Belle S, Marbaix S. Cost-effectiveness of sunitinib as second line treatment in patients with metastatic renal cancer in Belgium. Value Health 10(6), A329 (2007).
    • (2007) Value Health , vol.10 , Issue.6
    • Van Nooten, F.1    Dewilde, S.2    Van Belle, S.3    Marbaix, S.4
  • 35
    • 76949102287 scopus 로고    scopus 로고
    • Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-A in a Phase III trial: Final results and geographical analysis
    • Cella D, Michaelson MD, Bushmakin AG et al. Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-a in a Phase III trial: final results and geographical analysis. Br. J. Cancer 102(4), 658-664 (2010).
    • (2010) Br. J. Cancer , vol.102 , Issue.4 , pp. 658-664
    • Cella, D.1    Michaelson, M.D.2    Bushmakin, A.G.3
  • 36
    • 74249091926 scopus 로고    scopus 로고
    • Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: Bevacizumab in combination with interferon-A2a compared with sunitinib
    • Mickisch G, Gore M, Escudier B, Procopio G, Walzer S, Nuijten M. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-a2a compared with sunitinib. Br. J. Cancer 102(1), 80-86 (2010)
    • (2010) Br. J. Cancer , vol.102 , Issue.1 , pp. 80-86
    • Mickisch, G.1    Gore, M.2    Escudier, B.3    Procopio, G.4    Walzer, S.5    Nuijten, M.6
  • 37
    • 79952917182 scopus 로고    scopus 로고
    • Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy
    • Mickisch GH, Schwander B, Escudier B et al. Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy. Clinicoecon. Outcomes Res. 3, 19-27 (2011).
    • (2011) Clinicoecon. Outcomes Res. , vol.3 , pp. 19-27
    • Mickisch, G.H.1    Schwander, B.2    Escudier, B.3
  • 38
    • 60549104635 scopus 로고    scopus 로고
    • Metastatic renal cell cancer treatments: An indirect comparison meta-analysis
    • Mills EJ, Rachlis B, O'Regan C, Thabane L, Perri D. Metastatic renal cell cancer treatments: an indirect comparison meta-analysis. BMC Cancer 9(34) (2009).
    • (2009) BMC Cancer , vol.9 , pp. 34
    • Mills, E.J.1    Rachlis, B.2    O'Regan, C.3    Thabane, L.4    Perri, D.5
  • 39
    • 60849132105 scopus 로고    scopus 로고
    • Economic evaluation of sunitinib, sorafenib, bevacizumab/ interferon-A or temsirolimus in 1st-line treatment of metastatic renal cell carcinoma (mRCC): An indirect comparison
    • Abstract 5048
    • Benedict A, Charbonneau C, Hidi J, Kim ST, Négrier S. Economic evaluation of sunitinib, sorafenib, bevacizumab/ interferon-a or temsirolimus in 1st-line treatment of metastatic renal cell carcinoma (mRCC): an indirect comparison. J. Clin. Oncol. 26, (2008) (Abstract 5048).
    • (2008) J. Clin. Oncol. , vol.26
    • Benedict, A.1    Charbonneau, C.2    Hidi, J.3    Kim, S.T.4    Négrier, S.5
  • 40
    • 84857102720 scopus 로고    scopus 로고
    • Cost-effectiveness of sunitinib (SU), sorafenib (SFN), temsirolimus (TMS), and bevacizumab plus interferon-A (BEV/IFN) as 1st-line therapy for metastatic renal cell carcinoma (mRCC) - An indirect comparison
    • Benedict A, Charbonneau C, Kim ST, Négrier S. Cost-effectiveness of sunitinib (SU), sorafenib (SFN), temsirolimus (TMS), and bevacizumab plus interferon-a (BEV/IFN) as 1st-line therapy for metastatic renal cell carcinoma (mRCC) - an indirect comparison. Ann. Oncol. 19(Suppl. 8), 227 (2008).
    • (2008) Ann. Oncol. , vol.19 , Issue.SUPPL. 8 , pp. 227
    • Benedict, A.1    Charbonneau, C.2    Kim, S.T.3    Négrier, S.4
  • 41
    • 80051745686 scopus 로고    scopus 로고
    • Economic evaluation of sunitinib first-line for metastatic renal cell carcinoma versus sorafenib, temsirolimus and bevacizumab plus interferon-A in the Swedish health service setting
    • Sandin R, Munir U, Benedict A et al. economic evaluation of sunitinib first-line for metastatic renal cell carcinoma versus sorafenib, temsirolimus and bevacizumab plus interferon-a in the Swedish health service setting. Value Health 11(6), A468 (2008).
    • (2008) Value Health , vol.11 , Issue.6
    • Sandin, R.1    Munir, U.2    Benedict, A.3
  • 42
    • 80051749582 scopus 로고    scopus 로고
    • Cost-effectiveness of sunitinib (SU) vs sorafenib (SFN), temsirolimus (TMS) and bevacizumab plus interferon-A (BEV/IFN) as first-line therapy for metastatic renal cell carcinoma (mRCC) - Adaptation for the Swedish health service
    • Munir U, Benedict A, Borgman B et al. Cost-effectiveness of sunitinib (SU) vs sorafenib (SFN), temsirolimus (TMS) and bevacizumab plus interferon-a (BEV/IFN) as first-line therapy for metastatic renal cell carcinoma (mRCC) - adaptation for the Swedish health service. Ann. Oncol. 19(Suppl. 8), 228 (2008).
    • (2008) Ann. Oncol. , vol.19 , Issue.SUPPL. 8 , pp. 228
    • Munir, U.1    Benedict, A.2    Borgman, B.3
  • 43
    • 77958008740 scopus 로고    scopus 로고
    • Cost-effectiveness (CE) evaluation of sunitinib as first-line treatment for metastatic renal cell carcinoma (mRCC) in Spain. Abstract 409
    • San Francisco, CA, USA, 5-7 March
    • Calvo E, Maroto-Rey P, Gonzalez- Larriba JL et al. Cost-effectiveness (CE) evaluation of sunitinib as first-line treatment for metastatic renal cell carcinoma (mRCC) in Spain. Abstract 409. Presented at: ASCO Genitourinary Cancers Symposium. San Francisco, CA, USA, 5-7 March 2010.
    • (2010) ASCO Genitourinary Cancers Symposium
    • Calvo, E.1    Maroto-Rey, P.2    Gonzalez-Larriba, J.L.3
  • 44
    • 80051744913 scopus 로고    scopus 로고
    • Cost-effectiveness and cost-utility analysis of sunitinib (SU) vs sorafenib (SFN) and bevacizumab plus interferon-A (BEV/IFN) as first-line treatment for metastatic renal cell carcinoma (mRCC) in Spain
    • Diaz S, Calvo E, Maroto P, Puente J, Lopez- Brea M, Castellano D. Cost-effectiveness and cost-utility analysis of sunitinib (SU) vs sorafenib (SFN) and bevacizumab plus interferon-a (BEV/IFN) as first-line treatment for metastatic renal cell carcinoma (mRCC) in Spain. Ann. Oncol. 19(Suppl. 8), 227 (2008).
    • (2008) Ann. Oncol. , vol.19 , Issue.SUPPL. 8 , pp. 227
    • Diaz, S.1    Calvo, E.2    Maroto, P.3    Puente, J.4    Lopez- Brea, M.5    Castellano, D.6
  • 45
    • 84857101518 scopus 로고    scopus 로고
    • Cost-effectiveness analysis of first-line treatment for metastatic renal cell carcinoma in Colombia (ONCOLGroup study)
    • Rio de Janeiro, Brazil 10-12 September
    • Godoy JI, Cardona AF, Cáceres H et al. Cost-effectiveness analysis of first-line treatment for metastatic renal cell carcinoma in Colombia (ONCOLGroup study). Presented at: ISPOR 2 Latin America Conference, Rio de Janeiro, Brazil, 10-12 September 2009.
    • (2009) ISPOR 2 Latin America Conference
    • Godoy, J.I.1    Cardona, A.F.2    Cáceres, H.3
  • 46
    • 77950797255 scopus 로고    scopus 로고
    • Cost-effectiveness analysis of first-line treatment for metastatic renal cell carcinoma (mRCC) in Colombia (ONCOLGroup study
    • Abstract 16150
    • Godoy JI, Cardona AF, Cáceres H et al. Cost-effectiveness analysis of first-line treatment for metastatic renal cell carcinoma (mRCC) in Colombia (ONCOLGroup study). J. Clin. Oncol. 27(Suppl. 15) (2009) (Abstract 16150).
    • (2009) J. Clin. Oncol , vol.27 , Issue.SUPPL. 15
    • Godoy, J.I.1    Cardona, A.F.2    Cáceres, H.3
  • 47
    • 84857107071 scopus 로고    scopus 로고
    • Economic evaluation of sunitinib vs. interferon-A (IFN-a) in first-line treatment of metastatic renal cell carcinoma (mRCC) in Colombia
    • Cáceres H, Godoy JI, Cardona AF et al. Economic evaluation of sunitinib vs. interferon-a (IFN-a) in first-line treatment of metastatic renal cell carcinoma (mRCC) in Colombia. Value Health 11(3), A100 (2008).
    • (2008) Value Health , vol.11 , Issue.3
    • Cáceres, H.1    Godoy, J.I.2    Cardona, A.F.3
  • 48
    • 80051729677 scopus 로고    scopus 로고
    • Cost-effectiveness and cost-utility analysis of sunitinib vs sorafenib and bevacizumab plus interferon-A as first-line treatment for metastatic renal cell carcinoma in Mexico
    • Salinas-Escudero G, Contreras- Hernandez I, Mould-Quevedo J. Cost-effectiveness and cost-utility analysis of sunitinib vs sorafenib and bevacizumab plus interferon-a as first-line treatment for metastatic renal cell carcinoma in Mexico. Value Health 12(7), A497 (2009).
    • (2009) Value Health , vol.12 , Issue.7
    • Salinas-Escudero, G.1    Contreras-Hernandez, I.2    Mould-Quevedo, J.3
  • 49
    • 80051736063 scopus 로고    scopus 로고
    • Pharmacoeconomic evaluation of sunitinib malate for first-line treatment of metastatic renal cell carcinoma in Mexico
    • Orlando, FL, USA 18 May
    • Mould-Quevedo J, Tenorio C, Vargas J et al. Pharmacoeconomic evaluation of sunitinib malate for first-line treatment of metastatic renal cell carcinoma in Mexico. Presented at: ISPOR 14th Annual International Meeting. Orlando, FL, USA, 18 May 2009.
    • (2009) ISPOR 14th Annual International Meeting
    • Mould-Quevedo, J.1    Tenorio, C.2    Vargas, J.3
  • 50
    • 80051773070 scopus 로고    scopus 로고
    • Economic evaluation of sunitinib, sorafenib, bevacizumab/ interferon a and temsirolimus in first line treatment of metastatic renal cell carcinoma in Israel
    • Greenberg D. Economic evaluation of sunitinib, sorafenib, bevacizumab/ interferon a and temsirolimus in first line treatment of metastatic renal cell carcinoma in Israel. Value Health 12(3), A42 (2009).
    • (2009) Value Health , vol.12 , Issue.3
    • Greenberg, D.1
  • 51
    • 80051771661 scopus 로고    scopus 로고
    • Economic evaluation of sunitinib vs. interferon-A and bevacizumab plus interferon-A in the treatment of metastatic renal cell carcinoma (ccrm) - Brazilian private health system perspective
    • Teich V, Hashizume CM, Marinho T, Charbonneau C, Naves A. Economic evaluation of sunitinib vs. interferon-a and bevacizumab plus interferon-a in the treatment of metastatic renal cell carcinoma (ccrm) - Brazilian private health system perspective. Value Health 13(3), A37 (2010).
    • (2010) Value Health , vol.13 , Issue.3
    • Teich, V.1    Hashizume, C.M.2    Marinho, T.3    Charbonneau, C.4    Naves, A.5
  • 52
    • 75349093467 scopus 로고    scopus 로고
    • Cost-effectiveness of new targeted therapy sunitinib malate as second line treatment in metastatic renal cell carcinoma in Argentina
    • Aiello EC, Muszbek N, Richardet E, Lingua A, Charbonneau C, Remák E. Cost-effectiveness of new targeted therapy sunitinib malate as second line treatment in metastatic renal cell carcinoma in Argentina. Value Health 10(3), A127-A128 (2007
    • (2007) Value Health , vol.10 , Issue.3
    • Aiello, E.C.1    Muszbek, N.2    Richardet, E.3    Lingua, A.4    Charbonneau, C.5    Remák, E.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.